Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21(2):285–92.

Article  CAS  PubMed  Google Scholar 

Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatol. 2010;51(6):1972–8.

Article  Google Scholar 

Watanabe MA-O, Tozzi R, Risi R, Tuccinardi D, Mariani S, Basciani S, et al. Beneficial effects of the ketogenic diet on nonalcoholic fatty liver disease: A comprehensive review of the literature. Obes Rev. 2020;21(8):e13024.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fletcher JA, Deja S, Satapati S, Fu X, Burgess SC, Browning JD. Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver. JCI Insight. 2019;5(11):e127737.

Article  PubMed  Google Scholar 

Polidori D, Iijima H, Goda M, Maruyama N, Inagaki N, Crawford PA. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin. Diabetes Obes Metab. 2018;20(5):1321–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schaub JA, AlAkwaa FM, McCown PJ, Naik AS, Nair V, Eddy S, et al. SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes. J Clin Invest. 2023;133(5):e164486.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chiriacò M, Tricò D, Solini A. Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors. Curr Opin Pharmacol. 2022;66:102272.

Article  PubMed  Google Scholar 

Ramakrishnan S, Mooli RGR, Han Y, Fiorenza E, Kumar S, Bello F, et al. Hepatic ketogenesis regulates lipid homeostasis via ACSL1-mediated fatty acid partitioning. 2023;rs.3.rs-3147009.

Asif S, Kim RY, Fatica T, Sim J, Zhao X, Oh Y, et al. Hmgcs2-mediated ketogenesis modulates high-fat diet-induced hepatosteatosis. Mol Metab. 2022;61:101494.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cai D, Zhao Z, Hu J, Dai X, Zhong G, Gong J, et al. Identification of the Tumor Immune Microenvironment and Therapeutic Biomarkers by a Novel Molecular Subtype Based on Aging-Related Genes in Hepatocellular Carcinoma. Front Surg. 2022;9:836080.

Article  PubMed  PubMed Central  Google Scholar 

Cui X, Yun X, Sun M, Li R, Lyu X, Lao Y, et al. HMGCL-induced β-hydroxybutyrate production attenuates hepatocellular carcinoma via DPP4-mediated ferroptosis susceptibility. Hepatol Int. 2023;17(2):377–92.

Article  PubMed  Google Scholar 

Shi M, Zhang H, Wang W, Zhang X, Liu J, Wang Q, et al. Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease. J Diabetes Complications. 2023;37(10):108610.

Article  CAS  PubMed  Google Scholar 

Gaborit BA-OX, Ancel P, Abdullah AE, Maurice F, Abdesselam I, Calen A, et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc Diabetol. 2021;20(1):57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wallenius K, Kroon T, Hagstedt T, Löfgren L, Sörhede-Winzell M, Boucher J, et al. The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis. J Lipid Res. 2022;63(3):100176.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-Week results from a randomized controlled trial. Diabetes Care. 2018;41(9):1938–46.

Article  CAS  PubMed  Google Scholar 

Dandona P, Mathieu C, Phillip M, Hansen L, Tschöpe D, Thorén F, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018;41(12):2552–9.

Article  CAS  PubMed  Google Scholar 

Jeon JY, Ayyar VS, Mitra A. Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview. Pharm Res. 2022;39(8):1749–59.

Article  CAS  PubMed  Google Scholar 

Sou T, Hansen J, Liepinsh E, Backlund M, Ercan O, Grinberga S, et al. Model-informed drug development for antimicrobials: translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin. Clin Pharmacol Ther. 2021;109(4):1063-73.

Danhof M, De Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci. 2008;29(4):186–91.

Article  CAS  PubMed  Google Scholar 

Thongnak L, Chatsudthipong V, Kongkaew A, Lungkaphin A. Effects of dapagliflozin and statins attenuate renal injury and liver steatosis in high-fat/high-fructose diet-induced insulin resistant rats. Toxicol Appl Pharmacol. 2020;396:114997.

Article  CAS  PubMed  Google Scholar 

Honda K, Kamisoyama H, Tominaga Y, Yokota S, Hasegawa S. The molecular mechanism underlying the reduction in abdominal fat accumulation by licorice flavonoid oil in high fat diet-induced obese rats. Anim Sci J. 2009;80(5):562–9.

Article  CAS  PubMed  Google Scholar 

Long Q, Chen H, Yang W, Yang L, Zhang LA-O. Delphinidin-3-sambubioside from Hibiscus sabdariffa. L attenuates hyperlipidemia in high fat diet-induced obese rats and oleic acid-induced steatosis in HepG2 cells. Bioengineered. 2021;12(1):3837–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cook GA, Lavrentyev EN, Pham K, Park EA. Streptozotocin diabetes increases mRNA expression of ketogenic enzymes in the rat heart. Biochim Biophys Acta Gen Subj. 2017;1861(2):307–12.

Article  CAS  PubMed  Google Scholar 

Brunt EM, Fau KD, Wilson LA, Belt P, Neuschwander-Tetri BA, (CRN) NCRN. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53(3):810–20.

Article  CAS  PubMed  Google Scholar 

Männistö VT, Simonen M, Hyysalo J, Soininen P, Kangas AJ, Kaminska D, et al. Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans. Liver Int. 2015;35(7):1853–61.

Article  PubMed  Google Scholar 

Kleiner DE, Fau BE, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatol. 2005;41(6):1313–21.

Article  Google Scholar 

Mehlem A, Hagberg CE, Muhl L, Eriksson U, Falkevall A. Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nat Protoc. 2013;8(6):1149–54.

Article  PubMed  Google Scholar 

Maurer TS, Ghosh A, Haddish-Berhane N, Sawant-Basak A, Boustany-Kari CM, She L, Leininger MT, et al. Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology. AAPS J. 2011;13(4):576–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos. 2003;31(5):510–8.

Article  CAS  PubMed  Google Scholar 

Rieger TR, Allen RJ, Musante CJ. A Quantitative Systems Pharmacology Model of Liver Lipid Metabolism for Investigation of Non-Alcoholic Fatty Liver Disease. Front Pharmacol. 2022;13:910789.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ashworth WB, Davies NA-O, Bogle ID. A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD. PLoS Comput Biol. 2016;12(9):e1005105.

Article  PubMed  PubMed Central  Google Scholar 

Wang JA-O, Wen Y, Zhao WA-O, Zhang Y, Lin F, Ouyang C, et al. Hepatic conversion of acetyl-CoA to acetate plays crucial roles in energy stress. LID-